News & Updates

Allegra confirms route to FDA approval following successful pilot animal study

Sr–HT–Gahnite Spinal Cage Device
Allegra is now pleased to report the successful completion of the 8-week timeline for the large animal pilot study performed at SAHMRI (South Australian Health and Medical Research Institute).
The results of the study mark a pivotal milestone and a confirm a viable pathway to obtaining a 90 day FDA 510(k) clearance in the near future.

Read the ASX Announcement in full
Allegra confirms route to FDA approval following successful pilot animal study Sr–HT–Gahnite Spinal Cage Device

Keep up to date!

Receive newsletter updates weekly.

Sign Up